You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

~ Buy the ZYKADIA (ceritinib) Drug Profile, 2024 PDF Report in the Report Store ~

ZYKADIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zykadia patents expire, and what generic alternatives are available?

Zykadia is a drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this drug.

This drug has two hundred and eighty-six patent family members in fifty-four countries.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

DrugPatentWatch® Generic Entry Outlook for Zykadia

Zykadia was eligible for patent challenges on April 29, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 18, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZYKADIA?
  • What are the global sales for ZYKADIA?
  • What is Average Wholesale Price for ZYKADIA?
Summary for ZYKADIA
International Patents:286
US Patents:7
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 98
Clinical Trials: 11
Patent Applications: 761
Drug Prices: Drug price information for ZYKADIA
What excipients (inactive ingredients) are in ZYKADIA?ZYKADIA excipients list
DailyMed Link:ZYKADIA at DailyMed
Drug patent expirations by year for ZYKADIA
Drug Prices for ZYKADIA

See drug prices for ZYKADIA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZYKADIA
Generic Entry Dates for ZYKADIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for ZYKADIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZYKADIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Commissariat A L'energie AtomiquePhase 3
Plateforme labellisée Inca – Hôpital Européen Georges Pompidou, ParisPhase 3
Institut BergoniéPhase 3

See all ZYKADIA clinical trials

US Patents and Regulatory Information for ZYKADIA

ZYKADIA is protected by seven US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZYKADIA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZYKADIA

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods of using ALK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propan- e-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting ZYKADIA

TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Sign Up

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis ZYKADIA ceritinib TABLET;ORAL 211225-001 Mar 18, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib TABLET;ORAL 211225-001 Mar 18, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZYKADIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis ZYKADIA ceritinib TABLET;ORAL 211225-001 Mar 18, 2019 ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib TABLET;ORAL 211225-001 Mar 18, 2019 ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 ⤷  Sign Up ⤷  Sign Up
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ZYKADIA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Zykadia ceritinib EMEA/H/C/003819
Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.
Authorised no no no 2015-05-06
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ZYKADIA

When does loss-of-exclusivity occur for ZYKADIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4309
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN-4-IL-FENIL)-N4-[2-(PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Patent: 2395
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN-4-IL-FENIL)-N4-[2-(PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 11343775
Patent: Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl- 4-piperidin-4-yl-phenyl)-N4[2-(propane-2-sulfonyl)-phenyl] -pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2013015000
Patent: formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 21102
Patent: FORMES CRISTALLINES DE LA 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4-[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 13001723
Patent: Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico.
Estimated Expiration: ⤷  Sign Up

China

Patent: 3282359
Patent: Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Patent: 4262324
Patent: Crystalline Forms Of 5-chloro-n2-(2-isopropoxy-5-methyl- 4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl] -pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Patent: 6008462
Patent: 种ALK抑制剂的结晶形式 (Crystalline forms of ALK inhibitor)
Estimated Expiration: ⤷  Sign Up

Patent: 6831716
Patent: 种ALK抑制剂的结晶形式 (Crystallization of ALK inhibitor)
Estimated Expiration: ⤷  Sign Up

Patent: 7056751
Patent: 种ALK抑制剂的结晶形式 (crystalline forms of ALK inhibitor)
Estimated Expiration: ⤷  Sign Up

Patent: 2125884
Patent: 制备嘧啶-2,4-二胺二盐酸盐的方法 (Method for preparing pyrimidine-2, 4-diamine dihydrochloride)
Estimated Expiration: ⤷  Sign Up

Patent: 4989139
Patent: 制备嘧啶-2,4-二胺二盐酸盐的方法 (Method for preparing pyrimidine-2, 4-diamine dihydrochloride)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 01792
Patent: Formas cristalinas de 5-cloro-n2-(2-isoporpoxi 5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina.
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0171477
Estimated Expiration: ⤷  Sign Up

Patent: 0181737
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 19474
Estimated Expiration: ⤷  Sign Up

Patent: 21017
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 51918
Estimated Expiration: ⤷  Sign Up

Patent: 21171
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 13012770
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN-4-IL-FENIL)-N4-[2-(PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 51918
Patent: FORMES CRISTALLINES DE LA 5-CHLORO-N2-(2-ISOPROPOXY-5-MÉTHYL-4-PIPÉRIDIN-4-YL-PHÉNYL)-N4[2-(PROPANE-2-SULFONYL)-PHÉNYL]-PYRIMIDINE-2,4-DIAMINE (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 21171
Patent: FORMES CRISTALLINES DE LA 5-CHLORO-N2-(2-ISOPROPOXY-5-MÉTHYL-4-PIPÉRIDIN-4-YL-PHÉNYL)-N4[2-(PROPANE-2-SULFONYL)-PHÉNYL]-PYRIMIDINE-2,4-DIAMINE (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 53708
Patent: PROCÉDÉ POUR LA PRÉPARATION DE 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N-2-(ISOPROPYLSULFONYL)PHENYL)-2,4-DIAMINE DI-HYDROCHLORIDE (PROCESS FOR THE PREPARATION OF 5-CHLORO-N-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N-2-(ISOPROPYLSULFONYL)PHENYL)-2,4-DIAMINE DI-HYDROCHLORIDE)
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 1300153
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN-4-IL-FENIL)- N4-[2-(PROPAN-2-SULFONIL)-FENIL PIRIMIDIM-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 41845
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 6474
Patent: צורות גבישיות של 5-כלורו-n2-(2-איזופרופוקסי-5-מתיל-4-פיפרידנ-4-איל-פניל)-n4[2-(פרופאנ-2-סולפוניל)-פניל]פירימידינ-4,2-דיאמין (Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 16752
Estimated Expiration: ⤷  Sign Up

Patent: 13545812
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 51918
Estimated Expiration: ⤷  Sign Up

Patent: 21171
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 4810
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4-[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2, 4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Patent: 7742
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 8210
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN -4-IL-FENIL)-N4-[2- (PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2,4-DIAMI NA. (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERID IN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4 -DIAMINE.)
Estimated Expiration: ⤷  Sign Up

Patent: 13006952
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN -4-IL-FENIL)-N4-[2- (PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2,4-DIAMI NA. (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERID IN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4 -DIAMINE.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 771
Patent: طريقة لتحديد الخلايا التي لها حساسية من تعديل إشارة مستقبل عامل نمو الخلايا الليفية او الأصناف الاخرى.
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 0713
Patent: Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 140698
Patent: FORMAS CRISTALINAS DE 5-CLORO-N2-(2-ISOPROPOXI-5-METIL-4-PIPERIDIN-4-IL-FENIL)-N4-[2-(PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2, 4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 51918
Estimated Expiration: ⤷  Sign Up

Patent: 21171
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 51918
Estimated Expiration: ⤷  Sign Up

Patent: 21171
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 99785
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N2-(2-ИЗОПРОПОКСИ-5-МЕТИЛ-4-ПИПЕРИДИН-4-ИЛ-ФЕНИЛ)-N4-[2-(ПРОПАН-2-СУЛЬФОНИЛ)-ФЕНИЛ]-ПИРИМИДИН-2,4-ДИАМИНА (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4-[2-(PROPANE-2-SULPHONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 46159
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N2-(2-ИЗОПРОПОКСИ-5-МЕТИЛ-4-ПИПЕРИДИН-4-ИЛ-ФЕНИЛ)-N4-[2-(ПРОПАН-2-СУЛЬФОНИЛ)-ФЕНИЛ]-ПИРИМИДИН-2,4-ДИАМИНА (CRYSTAL FORMS 5-CHLORO-N2 - (2-ISOPROPOXY-5-METHYL-4-PIPERIDINE-4-YL-PHENYL) - N 4 - [2-(PROPANE-2-SULFONYL)- PHENYL] - PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 13132947
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N2-(2-ИЗОПРОПОКСИ-5-МЕТИЛ-4-ПИПЕРИДИН-4-ИЛ-ФЕНИЛ)-N4-[2-(ПРОПАН-2-СУЛЬФОНИЛ)-ФЕНИЛ]-ПИРИМИДИН-2,4-ДИАМИНА
Estimated Expiration: ⤷  Sign Up

Patent: 16136823
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N2-(2-ИЗОПРОПОКСИ-5-МЕТИЛ-4-ПИПЕРИДИН-4-ИЛ-ФЕНИЛ)-N4-[2-(ПРОПАН-2-СУЛЬФОНИЛ)-ФЕНИЛ]-ПИРИМИДИН-2,4-ДИАМИНА
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 771
Patent: KRISTALNI OBLICI 5-HLORO-N2-(2-IZOPROPOKSI-5-METIL-4-PIPERIDIN-4-IL-FENIL)-N4-[2-(PROPAN-2-SULFONIL)-FENIL]-PIRIMIDIN-2,4-DIAMINA (CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 0856
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Patent: 201510082X
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 51918
Estimated Expiration: ⤷  Sign Up

Patent: 21171
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1303599
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE2-,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2325775
Estimated Expiration: ⤷  Sign Up

Patent: 130130022
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Patent: 180032680
Patent: 5-클로로-N2--페닐]-피리미딘-2,4-디아민의 결정질 형태 (5--2-2--5--4--4---4[2--2--]--24- CRYSTALLINE FORMS OF 5-CHLORO-N2-2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-PROPANE-2-SULFONYL-PHENYL]-PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 190022903
Patent: 5-클로로-N2--페닐]-피리미딘-2,4-디아민의 결정질 형태 (5--2-2--5--4--4---4[2--2--]--24- CRYSTALLINE FORMS OF 5-CHLORO-N2-2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-PROPANE-2-SULFONYL-PHENYL]-PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 200039021
Patent: 5-클로로-N2--페닐]-피리미딘-2,4-디아민의 결정질 형태 (5--2-2--5--4--4---4[2--2--]--24- CRYSTALLINE FORMS OF 5-CHLORO-N2-2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-PROPANE-2-SULFONYL-PHENYL]-PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 43016
Estimated Expiration: ⤷  Sign Up

Patent: 96526
Estimated Expiration: ⤷  Sign Up

Patent: 05973
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 76343
Estimated Expiration: ⤷  Sign Up

Patent: 76344
Estimated Expiration: ⤷  Sign Up

Patent: 1307299
Patent: Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Patent: 1629021
Patent: Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 13000216
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZYKADIA around the world.

Country Patent Number Title Estimated Expiration
Japan 2013545812 ⤷  Sign Up
Australia 765151 ⤷  Sign Up
Japan 5208123 ⤷  Sign Up
Singapore 176311 METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS ⤷  Sign Up
European Patent Office 2537830 Composés et compositions en tant qu'inhibiteurs de protéine kinase (Compounds and compositions as protein kinase inhibitors) ⤷  Sign Up
Australia 2008252053 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZYKADIA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2091918 92785 Luxembourg ⤷  Sign Up PRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
1272477 132016000023559 Italy ⤷  Sign Up PRODUCT NAME: CERINITIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZIKADIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/999, 20150508
2091918 C20150037 00157 Estonia ⤷  Sign Up PRODUCT NAME: TSERITINIIB;REG NO/DATE: EU/1/15/999 08.05.2015
1272477 SPC/GB15/057 United Kingdom ⤷  Sign Up PRODUCT NAME: CERITINIB, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/15/999 20150508
2091918 15C0058 France ⤷  Sign Up PRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/999 20150508
2091918 PA2015034,C2091918 Lithuania ⤷  Sign Up PRODUCT NAME: CERITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/999 20150506
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.